Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.19, while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | VRTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $529.65 |
52-Week Low | $29.80 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.61, down 0.93% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has delivered high weekly distributions, with recent dividends ranging from $0.63 to $1.17, but faces concerns over net asset value erosion. Support is seen at $45, with resistance at $47.
The outlook is cautious due to structural NAV erosion risks highlighted by analysts. Investment opportunity lies in high income generation if AMD exhibits gradual volatility, but direct AMD exposure may be preferable for AI-driven upside. Key risks include yield sustainability and dependency on AMD's stock performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
